Track topics on Twitter Track topics that are important to you
For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual ...
Wolff–Parkinson–White syndrome (WPW) is a syndrome of pre-excitation of ventricles of the heart due to an accessory pathway known as the bundle of Kent. This accessory pathway is an abno...
UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It...
Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...
When margins are not good after DCIS surgery, recurrence rates at 10 years are double (or more) those of patients who have good margins. Medscape Medical News
Following breast-conserving surgery for ductal carcinoma in situ (DCIS), younger women face a higher risk than older patients for recurrence of both DCIS and invasive carcinomas.
Do regional practice patterns for radiotherapy for ductal carcinoma in situ (DCIS) breast cancer increase the likelihood of mastectomy when there is a second breast cancer in women who did not receive...
An expert review panel incorporating input from three of the top national
(MedPage Today) -- Wider not better at reducing recurrence risk
Not all DCIS is dangerous, and the prognostic genomic Oncotype DX DCIS Score allows for routine risk stratification of patients to avoid unnecessary treatment.
Lipofilling for breast reconstruction after mastectomy for breast cancer is not associated with a higher risk of disease recurrence, a new study reports. Plastic and Reconstructive Surgery
Optimal treatment for DCIS of the breast can be confusing. Do you have the tools to make tailored recommendations? Journal of Oncology Practice
Low-dose tamoxifen has comparable antiproliferative effect to the standard dose of 20 mg/day in biomarker trials, but its clinical efficacy remains unclear. We assessed the effect of low-dose tamoxife...
Local recurrence is a major concern in patients who have undergone surgery for ductal carcinoma in situ (DCIS). The present study assessed whether the expression levels of hormone receptors, human epi...
Introduction: Ductal carcinoma in situ (DCIS) is a premalignant lesion of the glandular component of the breast and a precursor lesion of invasive breast cancer. In recent decades the incidence of DCI...
Demand for conservative mastectomies continues to increase as more patients choose to undergo breast reconstruction, often with simultaneous contralateral prophylactic mastectomy (CPM). In addition, t...
Large regional variation exists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS). Although patients who do not receive initial radiotherapy for DCIS...